Canzoniero Jenna VanLiere, Park Ben Ho
Division of General Internal Medicine, Johns Hopkins, 600 N Wolfe St, Nelson 207, Baltimore, MD 21287, USA.
The Sidney Kimmel Comprehensive Cancer Institute at Johns Hopkins, 1650 Orleans Street, CRBI, Baltimore, MD 21287, USA.
Biochim Biophys Acta. 2016 Apr;1865(2):266-74. doi: 10.1016/j.bbcan.2016.03.006. Epub 2016 Mar 22.
Cell free DNA (cfDNA) are short fragments of nucleic acids present in circulation outside of cells. In patients with cancer, some portion of cfDNA is derived from tumor cells, termed circulating tumor DNA (ctDNA), and contains the same mutations and genetic changes as the cancer. The development of new, more effective methods to detect these changes has led to increased interest in developing ctDNA as a biomarker for cancer. Here we will review current literature on the use of ctDNA, with an emphasis on breast cancer, for cancer detection, prognosis, monitoring response to therapy, and tracking the rise of new mutant subclones.
游离DNA(cfDNA)是存在于细胞外循环中的短核酸片段。在癌症患者中,部分cfDNA来源于肿瘤细胞,称为循环肿瘤DNA(ctDNA),并含有与癌症相同的突变和基因变化。检测这些变化的更新、更有效方法的发展,引发了人们对将ctDNA开发为癌症生物标志物的兴趣增加。在此,我们将综述当前关于ctDNA应用的文献,重点关注乳腺癌,涉及癌症检测、预后、监测治疗反应以及追踪新突变亚克隆的出现。